NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63759-3048-01 | 63759-3048 | Pemetrexed disodium | Pemetrexed | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 3, 2023 | In Use | |
63759-3049-01 | 63759-3049 | Pemetrexed disodium | Pemetrexed | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 3, 2023 | In Use | |
63759-3050-01 | 63759-3050 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/100mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 3, 2023 | In Use | |
70121-2453-01 | 70121-2453 | Pemetrexed disodium | PEMRYDI RTU | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 6, 2023 | In Use | |
70121-2461-01 | 70121-2461 | Pemetrexed disodium | PEMRYDI RTU | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 6, 2023 | In Use | |
70121-2462-01 | 70121-2462 | Pemetrexed disodium | PEMRYDI RTU | 1000.0 mg/100mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 6, 2023 | In Use | |
70518-3777-00 | 70518-3777 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | June 28, 2023 | In Use | |
71335-2221-01 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-02 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-03 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-04 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-05 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-06 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-07 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
71335-2221-08 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug. 15, 2023 | In Use | |
81927-0204-01 | 81927-0204 | Methotrexate | JYLAMVO | 2.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 15, 2023 | In Use | |
62856-0389-01 | 62856-0389 | Eribulin mesylate | Halaven | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Nov. 15, 2010 | In Use | |
66302-0014-01 | 66302-0014 | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | Intravenous | March 10, 2015 | In Use | |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov. 25, 2020 | In Use | |
57894-0469-01 | 57894-0469 | Talquetamab | TALVEY | 3.0 mg/1.5mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug. 9, 2023 | In Use | |
57894-0470-01 | 57894-0470 | Talquetamab | TALVEY | 40.0 mg/mL | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | Subcutaneous | Aug. 9, 2023 | In Use | |
55566-8303-01 | 55566-8303 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | In Use | |||
55566-8403-01 | 55566-8403 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | In Use | |||
55566-8301-00 | 55566-8301 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used | ||
55566-8301-01 | 55566-8301 | Degarelix | Firmagon | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | March 2, 2009 | March 31, 2015 | No Longer Used |
Found 10,000 results in 8 milliseconds — Export these results